
clock.bio begins mission to extend health span by 20 years
Longevity biotech clock.bio has launched with $4 million in funding to develop regenerative medicines to prevent and treat age-related diseases. The company says its immediate objective is to decode all rejuvenation programmes present in human cells, to build an atlas of disease and rejuvenation targets for… Read More
